Patent Number: 8,871,714

Title: Hyperglycosylated human coagulation factor IX

Abstract: The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia.

Inventors: Bolt; Gert (Vaerloese, DK), Kristensen; Claus (Nivaa, DK)

Assignee: Novo Nordisk Health Care AG

International Classification: A61K 38/36 (20060101); C12P 21/04 (20060101); C07H 21/04 (20060101)

Expiration Date: 2018-10-28 0:00:00